Preprint / Version 1

Pharmaceutical and Non-Pharmaceutical Approaches to Managing Creutzfeldt-Jakob’s Disease Symptoms


  • Suhani Mehta High School Student
  • Katie Cording



Creutzfeldt-Jakob’s Diseas, Treatments, neurodegenerative disorders


Human prion diseases are part of a family of rare neurodegenerative disorders, affecting 1-2 out of every million people globally. The most prevalent type of prion disease is Creutzfeldt-Jakob disease, also known as CJD. Due to the misfolding of a prion protein, there is rapid degeneration of the brain. These misfolded prions lead to the formation of colonies, destroying surrounding brain tissue, leading to inevitable fatality. As the disease progresses, symptoms continue to worsen, ultimately causing complete mobility loss, dementia, slurring of words, abnormal jerking movements, and more. The central issue with CJD is a lack of treatment options available. As of now, there is no cure, instead, therapeutic methods focus on providing relief to the patient. Exploring potential therapies for CJD patients is crucial, as a patient’s physical and mental state is unpredictable throughout the journey with the disease. Furthermore, the rapidly progressing nature of the disease leaves little time for the trial of therapeutics, as it’s extremely difficult to predict the timeline of the  symptoms, and the symptoms require constant care and attention. Thus, it is necessary to find a manner in which symptoms can be managed as efficiently as possible, without disrupting the patient’s comfort. This review summarizes a wide variety of pharmaceutical and non-pharmaceutical therapies for CJD patients, with the goal of highlighting therapies that best relieve patients of their symptoms. Ranging from the potential use of antibodies to acute rehabilitation, these studies explore methods that can help CJD patients live out the rest of their lives in the most satisfactory manner.


“What Is Acute Rehabilitation?” Santé Cares, 21 Dec. 2016, Accessed 4 Sept. 2023.

Alcohol and Drug Foundation. “Benzodiazepines - ADF - Alcohol & Drug Foundation.” ADF - Alcohol & Drug Foundation, 10 Jan. 2023,

“Art Therapy | Psychology Today.”, Accessed 4 Sept. 2023.

Ashraf, Ghulam Md, et al. “Protein Misfolding and Aggregation in Alzheimer’s Disease and Type 2 Diabetes Mellitus.” CNS & Neurological Disorders Drug Targets, vol. 13, no. 7, 2014, pp. 1280–1293,

Basit, Hajira, and Chadi I. Kahwaji. “Clonazepam.” PubMed, StatPearls Publishing, 2020,

Bielecki, Joseph E., and Prasanna Tadi. “Therapeutic Exercise.” PubMed, StatPearls Publishing, 2021,

CDC. “Occurrence and Transmission | Creutzfeldt-Jakob Disease, Classic (CJD) | Prion Disease | CDC.”, 14 Nov. 2022,

Centers for Disease Control and Prevention. “Bovine Spongiform Encephalopathy (BSE).”

Centers for Disease Control and Prevention, 2019,

Cleveland Clinic. “Antibodies: Definition, Types & Function.” Cleveland Clinic, 5 June 2022,

Clinical Policy Title: Neuromuscular Reeducation Clinical.

Copeland, Royce, et al. “The Management of Newly Diagnosed Probable Creutzfeldt-Jakob Disease in Acute the Management of Newly Diagnosed Probable Creutzfeldt-Jakob Disease in Acute Rehabilitation Setting: A Case Report Rehabilitation Setting: A Case Report.” Clinical Medical Research and Healthcare Delivery, vol. 2, no. 3, 2022,, Accessed 3 Mar. 2023.

“Creutzfeldt-Jakob Disease (CJD): Types, Causes, Symptoms & Outlook.” Cleveland Clinic,

“Creutzfeldt-Jakob Disease Symptoms.”,

Dhuri, Karishma, et al. “Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development.” Journal of Clinical Medicine, vol. 9, no. 6, 26 June 2020, p. 2004,

“Diagnostic Criteria | Creutzfeldt-Jakob Disease, Classic (CJD) | Prion Disease | CDC.”, 25 Jan. 2019,

Edinoff, Amber N., et al. “Benzodiazepines: Uses, Dangers, and Clinical Considerations.” Neurology International, vol. 13, no. 4, 10 Nov. 2021, pp. 594–607,,

Emmady, Prabhu D., and Arayamparambil C. Anilkumar. “EEG Abnormal Waveforms.” PubMed, StatPearls Publishing, 2023, Accessed 4 Sept. 2023.

Eng, Janice J, and Pei-Fang Tang. “Gait Training Strategies to Optimize Walking Ability in People with Stroke: A Synthesis of the Evidence.” Expert Review of Neurotherapeutics, vol. 7, no. 10, Oct. 2007, pp. 1417–1436,,

European Centre for Disease Prevention and Control. “Facts about Variant Creutzfeldt-Jakob Disease.” European Centre for Disease Prevention and Control, 26 June 2017,

“Familial Prion Disease.” Memory and Aging Center, Accessed 4 Sept. 2023.

Harish, S, et al. “Flupirtine : Clinical Pharmacology.” Journal of Anaesthesiology Clinical Pharmacology, vol. 28, no. 2, 2012, p. 172,,

Ho, Mai-Lan. “Creutzfeldt-Jakob Disease | Radiology Reference Article |” Radiopaedia,

Jewett, Benjamin E., and Bicky Thapa. “Physiology, NMDA Receptor.” PubMed, StatPearls Publishing, 2022,

John Hopkins Medicine. “Prion Diseases.” Johns Hopkins Medicine, 2019,

Kim, Yong-Chan, and Byung-Hoon Jeong. “Creutzfeldt-Jakob Disease Incidence, South Korea, 2001–2019.” Emerging Infectious Diseases, vol. 28, no. 9, 1 Sept. 2022, pp. 1863–1866,, Accessed 4 Sept. 2023.

Legname, Giuseppe. “Elucidating the Function of the Prion Protein.” PLOS Pathogens, vol. 13, no. 8, 31 Aug. 2017, p. e1006458,

“Lumbar Puncture.”,

McPherson, Christopher, and Vincent DiNapoli. “Brain Biopsy | Mayfield Brain & Spine.”, Accessed 4 Sept. 2023.

Mead, Simon, et al. “Prion Protein Monoclonal Antibody (PRN100) Therapy for Creutzfeldt–Jakob Disease: Evaluation of a First-In-Human Treatment Programme.” The Lancet Neurology, vol. 21, no. 4, Apr. 2022, pp. 342–354,

Miller, Colton , and Edward Harris. “Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization.” RNA & DISEASE, 7 Nov. 2016, Accessed 6 May 2019.

National Institute on Aging. “Parkinson’s Disease.” National Institute on Aging, 14 Apr. 2022,

“New Drug: Midodrine for Orthostatic Hypotension.” Australian Prescriber, 17 Dec. 2020, Accessed 9 Jan. 2021.

NHS. “Creutzfeldt-Jakob Disease.” NHS, 2019,

NHS Choices. “Diagnosis - Creutzfeldt-Jakob Disease.” NHS, 2020,

Nishimura, Yoshito, et al. “A Nationwide Trend Analysis in the Incidence and Mortality of Creutzfeldt–Jakob Disease in Japan between 2005 and 2014.” Scientific Reports, vol. 10, no. 1, 23 Sept. 2020, p. 15509,,

“PRNP Gene: MedlinePlus Genetics.”,

Qamar, Muhammad Sohaib, et al. “Creutzfeldt-Jakob Disease with Atypical Magnetic Resonance Imaging Features.” Cureus, 2 Nov. 2020, Accessed 19 Nov. 2020.

Raymond, Gregory J., et al. “Antisense Oligonucleotides Extend Survival of Prion-Infected Mice.” JCI Insight, vol. 4, no. 16, 22 Aug. 2019,,

Reimhult, Erik . “A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics.” ProQuest, vol. 23, no. 3, 2022, p. 1851,,

Singh, Ravneet, and Nazia M Sadiq. “Cholinesterase Inhibitors.”, StatPearls Publishing, 19 Jan. 2022,

“Sodium Valproate: Medicine to Treat Epilepsy and Bipolar Disorder.”, 27 Sept. 2018,

“The Science behind Parkinson’s.” Cure Parkinson’s,

Valqui, Melissa. “Steric Hindrance.” ChemTalk, 9 June 2021, Accessed 4 Sept. 2023.

WIESER, H, et al. “EEG in Creutzfeldt–Jakob Disease.” Clinical Neurophysiology, vol. 117, no. 5, May 2006, pp. 935–951,

Zerr, I., et al. “Detection of 14-3-3 Protein in the Cerebrospinal Fluid Supports the Diagnosis of Creutzfeldt-Jakob Disease.” Annals of Neurology, vol. 43, no. 1, 1 Jan. 1998, pp. 32–40,, Accessed 27 July 2022.